Assessment of recovery time for the collagen products Dermicol-P35 27G and 30G.
BACKGROUND
Dermicol-P35 27G and 30G are purified advanced collagen dermal fillers that are effective and well tolerated for cosmetic procedures.


OBJECTIVE
The primary objectives of this study were to: (1) document recovery time and return to daily activities after treatment with Dermicol-P35 27G, 30G, or both; and (2) assess the immediate adverse effects of these products and monitor their time to resolution.


METHODS
In all, 30 patients were treated with Dermicol-P35 27G, 30G, or both in nasolabial folds, lips, corners of the mouth, vermillion border, marionette lines, or a combination of these and monitored for 7 days. Comfort with resuming daily routine, adverse events, and satisfaction with results were documented by patients in diaries. The clinician assessed aesthetic improvement and rated satisfaction with results.


RESULTS
The majority of patients (63.4%) were very comfortable or comfortable returning to their daily routine immediately postprocedure. Most patients (86.7%) participated in normal work or social events within 2 days of treatment. Adverse events were mild to moderate and were resolved or tolerable by day 7. The clinician assessed that most patients had between 50% and 100% improvement over baseline for all procedures at all time points. Clinician and patients were very satisfied or satisfied with aesthetic results at days 2 and 7 postprocedure.


CONCLUSIONS
The limitations of this study were the small number of patients, the assessment of short-term results, and the lack of touch-up injections.


CONCLUSIONS
Treatment with Dermicol-P35 27G, 30G, or both allowed for rapid return to daily activities and produced only transient and tolerable adverse events.
Solish
Nowell J
NJ
Division of Dermatology, University of Toronto, Women's College Hospital, 76 Grenville St, Toronto, ON M5S 1B2, Canada. n.solish@utoronto.ca
D000328:Adult; D000818:Animals; D001672:Biocompatible Materials / Q000008:administration & dosage / Q000009:adverse effects; D003094:Collagen / Q000008:administration & dosage* / Q000009:adverse effects; D003357:Cosmetic Techniques / Q000009:adverse effects; D005145:Face; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D008046:Lip; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D012060:Rejuvenation; D015595:Skin Aging / Q000187:drug effects; D013552:Swine; D016896:Treatment Outcome
D001672:Biocompatible Materials; C549013:dermicol-P35 27G; C530016:dermicol-P35 30G; D003094:Collagen